Duchenne Muscular Dystrophy

Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
Xconomy
Wed, 06/27/18 - 11:56 am
Summit Therapeutics
ezutromid
clinical trials
Duchenne Muscular Dystrophy
[video/transcript]Sarepta Therapeutics Could Be Onto Something Big
Motley Fool
Mon, 06/25/18 - 07:26 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Early access to Santhera’s DMD therapy Raxone extended in the UK
Pharma Times
Fri, 06/22/18 - 10:26 pm
UK
Santhera
Raxone
Duchenne Muscular Dystrophy
3 patients add $2.5B to Sarepta's value
Biopharma Dive
Tue, 06/19/18 - 09:45 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’
Stat
Tue, 06/19/18 - 10:55 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
clinical trials
As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy
Xconomy
Mon, 06/18/18 - 11:25 am
Duchenne Muscular Dystrophy
Solid Biosciences
Sarepta Therapeutics
SGT-001
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Endpoints
Thu, 05/3/18 - 11:14 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Exondys 51
CHMP
Europe
Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment
CP Wire
Thu, 04/26/18 - 09:49 am
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment
Wed, 04/25/18 - 07:40 pm
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development
Endpoints
Wed, 04/25/18 - 09:50 am
Daiichi Sankyo
Duchenne Muscular Dystrophy
DS-5141
Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)
CP Wire
Wed, 04/18/18 - 09:54 am
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
clinical trials
Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy
CP Wire
Wed, 04/18/18 - 09:43 am
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
restructuring
layoffs
Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)
Wed, 04/18/18 - 09:40 am
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy
Tue, 04/17/18 - 06:50 pm
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
Pfizer Commences Ph Ib Trial With Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
CP Wire
Thu, 04/12/18 - 11:51 am
Pfizer
PF-06939926
Duchenne Muscular Dystrophy
gene therapy
Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
Endpoints
Fri, 04/6/18 - 07:39 pm
Sarepta Therapeutics
patients
patents
Exondys 51
Duchenne Muscular Dystrophy
Solid Bio's DMD gene therapy graduates from partial FDA hold to full-on clinical hold
Fierce Biotech
Wed, 03/14/18 - 09:29 pm
Solid Biosciences
gene therapy
FDA
DMD
Duchenne Muscular Dystrophy
Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end
Stat
Mon, 03/12/18 - 09:37 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
golodirsen
Exondys 51
Did the FDA just leave the door cracked open for PTC’s Duchenne drug after repeated slapdowns?
Endpoints
Tue, 02/20/18 - 09:17 am
FDA
PTC Therapeutics
DMD
Duchenne Muscular Dystrophy
ataluren
Sarepta halts its golodirsen Duchenne MD study in UK after patient experiences adverse event
Endpoints
Fri, 02/9/18 - 09:35 am
Sarepta Therapeutics
golodirsen
Duchenne Muscular Dystrophy
UK

Pages